These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37698031)

  • 1. A prospective longitudinal analysis of the predictors of amenorrhea after breast cancer chemotherapy: Impact of BRCA pathogenic variants.
    Oktay KH; Turan V; Bedoschi G; Abdo N; Bang H; Goldfarb S
    Cancer Med; 2023 Sep; 12(18):19225-19233. PubMed ID: 37698031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103.
    Ruddy KJ; O'Neill A; Miller KD; Schneider BP; Baker E; Sparano JA; Dang C; Northfelt DW; Sledge GW; Partridge AH
    Breast Cancer Res Treat; 2014 Apr; 144(3):591-7. PubMed ID: 24584876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer.
    Dezellus A; Barriere P; Campone M; Lemanski C; Vanlemmens L; Mignot L; Delozier T; Levy C; Bendavid C; Debled M; Bachelot T; Jouannaud C; Loustalot C; Mouret-Reynier MA; Gallais-Umbert A; Masson D; Freour T
    Eur J Cancer; 2017 Jul; 79():72-80. PubMed ID: 28463758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer.
    Goldfarb SB; Turan V; Bedoschi G; Taylan E; Abdo N; Cigler T; Bang H; Patil S; Dickler MN; Oktay KH
    Breast Cancer Res Treat; 2021 Jan; 185(1):165-173. PubMed ID: 32930927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-müllerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy.
    Fréour T; Barrière P; Masson D
    Eur J Cancer; 2017 Mar; 74():1-8. PubMed ID: 28135602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer.
    Minton SE; Munster PN
    Cancer Control; 2002; 9(6):466-72. PubMed ID: 12514564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer.
    Anderson RA; Rosendahl M; Kelsey TW; Cameron DA
    Eur J Cancer; 2013 Nov; 49(16):3404-11. PubMed ID: 23968732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy-induced amenorrhea, menopause-specific quality of life, and endocrine profiles in premenopausal women with breast cancer who received adjuvant anthracycline-based chemotherapy: a prospective cohort study.
    Yoo C; Yun MR; Ahn JH; Jung KH; Kim HJ; Kim JE; Park JY; Park KO; Yoon DH; Kim SB
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):565-75. PubMed ID: 23842722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.
    Munster PN; Moore AP; Ismail-Khan R; Cox CE; Lacevic M; Gross-King M; Xu P; Carter WB; Minton SE
    J Clin Oncol; 2012 Feb; 30(5):533-8. PubMed ID: 22231041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal study of AMH variations in 122 Adolescents and Young Adults (AYA) and non-AYA lymphoma patients to evaluate the chemo-induced ovarian toxicity to further personalise fertility preservation counselling.
    Decanter C; Delepine J; Behal H; Manier S; Bruno B; Barbatti M; Robin C; Labreuche J; Morschhauser F; Pigny P
    Hum Reprod; 2021 Sep; 36(10):2743-2752. PubMed ID: 34417822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of ovarian function after chemotherapy in women with early and locally advanced breast cancer from Serbia.
    Malisic E; Susnjar S; Milovanovic J; Todorovic-Rakovic N; Kesic V
    Arch Gynecol Obstet; 2018 Feb; 297(2):495-503. PubMed ID: 29101609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment anti-Mullerian hormone-based nomogram predicts menstruation status after chemotherapy for premenopausal women with hormone receptor-positive early breast cancer.
    Xue C; Wei W; Sun P; Zheng W; Diao X; Xu F; Huang J; An X; Xia W; Hong R; Jiang K; Huang R; Yuan Z; Wang S; Li A; Zou R; Shi Y
    Breast Cancer Res Treat; 2019 Feb; 173(3):619-628. PubMed ID: 30392113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial.
    Wenners A; Grambach J; Koss J; Maass N; Jonat W; Schmutzler A; Mundhenke C
    BMC Cancer; 2017 Sep; 17(1):632. PubMed ID: 28877720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of chemotherapy-induced ovarian failure in premenopausal women undergoing chemotherapy for breast cancer.
    Tiong V; Rozita AM; Taib NA; Yip CH; Ng CH
    World J Surg; 2014 Sep; 38(9):2288-96. PubMed ID: 24700093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients.
    Zhou WB; Yin H; Liu XA; Zha XM; Chen L; Dai JC; Tao AD; Chen L; Ma JJ; Ling LJ; Wang S
    BMC Cancer; 2010 Jun; 10():281. PubMed ID: 20540745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer.
    Abusief ME; Missmer SA; Ginsburg ES; Weeks JC; Partridge AH
    Cancer; 2010 Feb; 116(4):791-8. PubMed ID: 20052714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane.
    Tham YL; Sexton K; Weiss H; Elledge R; Friedman LC; Kramer R
    Am J Clin Oncol; 2007 Apr; 30(2):126-32. PubMed ID: 17414460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer.
    Anderson RA; Cameron DA
    J Clin Endocrinol Metab; 2011 May; 96(5):1336-43. PubMed ID: 21325458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer.
    Han HS; Ro J; Lee KS; Nam BH; Seo JA; Lee DH; Lee H; Lee ES; Kang HS; Kim SW
    Breast Cancer Res Treat; 2009 May; 115(2):335-42. PubMed ID: 18506620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of recovery from amenorrhea in premenopausal breast cancer patients receiving adjuvant chemotherapy in the taxane era.
    Minisini AM; Menis J; Valent F; Andreetta C; Alessi B; Pascoletti G; Piga A; Fasola G; Puglisi F
    Anticancer Drugs; 2009 Jul; 20(6):503-7. PubMed ID: 19339872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.